Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Merger or Acquisition (May 2005)
35 slides from Daiichi Sankyo's merger presentation, May 13, 2005
Slide 1: A Global Pharma Innovator
A Global Pharma Innovator May 13, 2005 (Friday)
Slide 2: Focus of this Presentation
Focus of this Presentation This presentation contains statements concerning forecasts for Sankyo Co., Ltd. (“Sankyo”), Daiichi Pharmaceutical Co., Ltd. (“Daiichi”) and their group companies. These statements are based on assumptions and judgments made with information available at the time of prepar
Slide 3: Contents
Contents 1 Transaction Overview 2 Benefits of Transaction 3 Integration Strategy and Global Growth 4 Management Structure and Integration Schedule 2
Slide 4: 1-1 Profile of the New Company
1-1 Profile of the New Company Name DAIICHI SANKYO COMPANY, LIMITED Head office location 3-5-1 Nihonbashi Honcho, Chuo-ku, Tokyo Date of both September 21, 2005 companies’ delisting Stock transfer date September 28, 2005 Listing of the holding September 28, 2005 company Stock transfer ratio New comp
Slide 5: 1-2 Vision for Business Integration
1-2 Vision for Business Integration Sankyo and Daiichi: Creating a global pharma innovator Capability to create innovative products Operating efficiency at highest industry standard Established global presence and growth potential Strengthen formidable position in Japan Accelerated earnings growth M
Slide 6: 1-3 Accelerated Earnings Growth - Pharma Business Targets
1-3 Accelerated Earnings Growth -Pharma Business Targets * - 1 Integration will accelerate earnings growth Operating income expected to exceed ¥250bn in FY09 Ensure R&D funding necessary as a Global Pharma Innovator Unit: Billions of yen FY04 FY07 FY09 Net sales 758 762 932 CAGR*3 Ethical Drug Busin
Slide 7: 1-4 Increased Shareholder Value
1-4 Increased Shareholder Value Sales and cost synergies will increase shareholder value Leveraging Global Pharma Innovator platform will generate additional potential synergies Potential synergies from Global Pharma Innovator Possible platform negative Integration Sales and synergies* costs cost sy
Slide 8: 1-5 Shareholder Returns at Highest Levels in Japan
1-5 Shareholder Returns at Highest Levels in Japan Committed to return value to shareholders at highest levels in Japan Committed to growing DPS (dividend per share) in FY05 and increase further Targeted to deliver DOE (Dividend on Equity) of 5% for FY09 7
Slide 9: 1-6 Basic Strategies for Integration and Global Growth
1-6 Basic Strategies for Integration and Global Growth Strengthen the earnings base in Japan Pursue global growth centered on the U.S. market, realizing rapid earnings growth Japanese Business U.S. Business Establish a strong Pursue Pursue global global growth growth earnings base R&D Customer reach
Slide 10: Benefits of Transaction
1 Transaction Overview 2 Benefits of Transaction 3 Integration Strategy and Global Growth 4 Management Structure and Integration Schedule 9
Slide 11: 2-1 Integration Benefits
2-1 Integration Benefits -Pharmacuetical Business Targets/Consolidated Operating Profit- Integration will generate significant increases in earnings Cost synergies far exceed possible negative synergies FY07 FY07 FY09 FY09 Possible Sales negative synergies*2 synergies*3 Possible ¥36bn (¥19bn) R&D in
Slide 12: 2-2 Cost Synergy Breakdown
2-2 Cost Synergy Breakdown -Pharmaceutical Business Targets - Business/Expense FY07 FY09 Principal Measures Domestic Cost of sales and ¥23bn ¥29bn ! Reduce purchasing and outsourcing business SG&A expenses (excluding ! Reduce sales promotion and personnel advertising expenses expenses) ! Reduce purc
Slide 13: 2-3 Number of Personnel
2-3 Number of Personnel* -Pharmaceutical Business Targets - 15,000 personnel by FY09 Over 40% of personnel to be based overseas, due to expansion of U.S. business Unit: Persons 15,500 15,000 14,600 2,900 (19%) 4,800 3,300 3,300 1,900 (31%) (23%) 5,700 (22%) 6,300 (12%) (39%) (42%) 2,400 3,000 (16%)
Slide 14: 2-4.1 Sales Synergies
2-4.1 Sales Synergies -Pharmaceutical Business Targets- Grow sales of the Company’s high-margin products, both in Japan and overseas Income Income increase increase benefits benefits Earnings Earnings increase increase benefits benefits (net (net sales) sales) (operating (operating income*) income*)
Slide 15: 2-4.2 Measures to Generate Sales Synergies
2-4.2 Measures to Generate Sales Synergies - Domestic Ethical Drugs - Collaboration*1 will begin in October 2005 Focus on leading products from each company, in major drug markets !Olmetec, Mevalotin, Cravit, Calblock, etc. Strategic utilization of the formidable marketing abilities of both companie
Slide 16: 2-4.3 Emphasis on the Cardiovascular Disease Field
2-4.3 Emphasis on the Cardiovascular Disease Field Numerous products and development projects Extensive skills and knowledge in cardiovascular-related fields Maximization of Olmetec at the earliest opportunity through prioritization in the cardiovascular field !Begin collaboration from October 2005
Slide 17: 2-4.4 Generating Sales Synergies - Olmetec
2-4.4 Generating Sales Synergies – Olmetec – 1 2 ARB* ARB*1 Sales Sales in in Japan* Japan*2 Preceding three Target products*3 FY09 Domestic Sales of ¥100bn Sales Raise to the level of the preceding three products (Current drug price basis) Olmetec ・Olmetec already Best in Class ARB in US/Europe Mon
Slide 18: 2-5 Focus on the Pharmaceutical Business
2-5 Focus on the Pharmaceutical Business The Daiichi Sankyo Group will focus on the pharmaceutical business All 15 non-pharma affiliates will be made wholly independent Target for completion March 2007 Affiliates currently represent ! ¥170bn in sales ! ¥9bn in operating income 17
Slide 19: 2-6 Integration Costs
2-6 Integration Costs One-time integration costs estimated at ¥118bn Of which, more than 90% are expected to be incurred in FY06* Unit: Billions of yen Cost Item by FY06 Personnel-related Additional retirement payments 50 Transfer charge 37 Other 3 IT integration 6 Business location transfer 3 Corpo
Slide 20: Integration Strategy and Global Growth
1 Transaction Overview 2 Benefits of Transaction 3 Integration Strategy and Global Growth 4 Management Structure and Integration Schedule 19
Slide 21: 3-1 Enhanced R&D Capability
3-1 Enhanced R&D Capability Exploratory Research Developmental Research Clinical Development Search for development candidates Create highly that fulfill medical needs competitive products Enhancement of development Reinforce research skills, resources resources and mutual utilization of and technol
Slide 22: 3-2.1 Global Development Pipeline - US Example
3-2.1 Global Development Pipeline –US Example– Strong and sustainable pipeline Concentrate on CS-747, DU-176b and CS-505, bringing these to market as early as possible Development Therapeutic Area Phase 1 Phase 2 Phase 3 candidates* ! CS-3030 Cardiovascular ! SUN N8075 ! DU-176b ! CS-505 ! CS-747 !
Slide 23: 3-2.2 Varied Approach to Cardiovascular and Glucose Metabolic Diseases
3-2.2 Varied Approach to Cardiovascular and Glucose Metabolic Diseases Blood vessel thickening Glucose/lipid metabolism Anti-platelet CS-747 DZ-697b* Anti-arteriosclerosis Anti-FXa CS-505 DU-176b CS-3030* Anti-diabetes WelChol diabetes Platelet CS-011 CS-917 coagulation SNK-860 system Anti-hyperlipi
Slide 24: 3-3 Unification of Development Pipeline Management
3-3 Unification of Development Pipeline Management Establish a unification process by September 2005 Unify the pipeline priorities of both companies from October 2005 Concentrate global development resources more selectively Increase development speed by mutually utilizing infrastructure and experti
Slide 25: 3-4 Greater Earnings through In-House Development, Sales and Marketing
3-4 Greater Earnings through In-House Development, Sales and Marketing Following expansion, utilize in-house development, sales and marketing for priority products Significant boost in income and earnings expected Product contribution margin model Marketing option Example product Product value (NPV)
Slide 26: 3-5 Strengthen Human Resources Infrastructure
3-5 Strengthen Human Resources Infrastructure Effectively utilize the exceptional employees of both companies through the introduction and strict adherence to a new HR system ! Introduction of a new HR system " Build new classification, compensation and evaluation systems " Ensure equal employment o
Slide 27: Management Structure and Integration Schedule
1 Transaction Overview 2 Benefits of Transaction 3 Integration Strategy and Global Growth 4 Management Structure and Integration Schedule 26
Slide 28: 4-1 Governance and Responsibilities
4-1 Governance and Responsibilities Adoption of the Corporate Officer System and Board of Auditors will provide for responsive management Oversight and conduct of operations will be kept separate, handled by the Board of the Directors and the CEO, respectively Management bodies/positions Responsibil
Slide 29: 4-2 Directors and Auditors (planned)
4-2 Directors and Auditors (planned) Directors Auditors Chairman Kiyoshi Morita Standing auditors Kozo Wada Atsuo Inoue President and CEO Takashi Shoda Outside auditors Kaoru Shimada Directors Hiroyuki Nagasako Koukei Higuchi Hideho Kawamura Yasuhiro Ikegami Tsutomu Une Outside directors Kunio Nihir
Slide 30: 4-3 Structure and Functions of the Holding Company
4-3 Structure and Functions of the Holding Company Board Board of of Directors Directors CEO CEO Management Management Committee Committee Auditors Auditors Corporate Corporate Corporate Corporate Business Business Business Business Corporate Corporate Administration Administration Communications Co
Slide 31: 4-4 Approach to Integration
4-4 Approach to Integration Combination of “Integrate then Go” and “Virtual Integration” Maximum cost synergies are assured, while integration in domestic business and R&D begins in October 2005 Advantage of “Integrate then Go” Advantage of “Go then Integrate” ! Unification of administrative, IT and
Slide 32: 4-5 Integration Schedule
4-5 Integration Schedule ! Begin domestic sales collaboration Oct.2005 ! Begin unification of development pipeline ! Integration of U.S. sales functions Apr.2006 ! Integration of Europe and U.S. development functions ! Integration of the Healthcare Business ! Independence of non-pharma businesses ou
Slide 33: Daiichi Sankyo building a strong global competitor
Global Pharma Innovator Daiichi Sankyo building a strong global competitor 32
Slide 34: Filings with the U.S. SEC
Filings with the U.S. SEC Daiichi Pharmaceutical Co., Ltd. and Sankyo Company, Limited may file a registration statement on Form F-4 with the U.S. SEC in connection with the proposed business combination of Daiichi and Sankyo under a new holding company by way of a joint stock transfer. The Form F-4
Slide 35: Forward-Looking Statements
Forward-Looking Statements This communication contains forward-looking information and statements about Daiichi and Sankyo and their combined businesses after completion of the joint stock transfer. Forward-looking statements are statements that are not historical facts. These statements include fin
Daiichi Sankyo Company — Merger or Acquisition (May 2005) on 6ix